Log In
Print this Print this

tucatinib (ONT-380) (formerly ARRY-380)

  Manage Alerts
Collapse Summary General Information
Company Array BioPharma Inc.
DescriptionEpidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu) inhibitor
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionEpidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive metastatic breast cancer
Regulatory Designation U.S. - Fast Track (Treat HER2-positive metastatic breast cancer)
PartnerCascadian Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone









Get a free BioCentury trial today